RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Clinical trials for RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to halt rare blood cancers
Disease control OngoingThis study tests a new drug, seclidemstat, combined with a standard treatment (azacitidine) for people with certain blood cancers (myelodysplastic syndromes and chronic myelomonocytic leukemia). The goal is to find the best dose and see if the combination can shrink or control th…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug combo targets Hard-to-Treat blood cancers
Disease control OngoingThis study tests a combination of two drugs, azacitidine and quizartinib, for adults with myelodysplastic syndromes or related blood cancers that have specific gene changes (FLT3 or CBL). The goal is to find the best dose and see how well the drugs control the cancer. About 30 pe…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New drug combo offers hope for Tough-to-Treat blood cancers
Disease control OngoingThis study tests a combination of two drugs, venetoclax and azacitidine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) that has returned or not responded to prior therapy. The goal is to find the best dose and see how well the c…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New antibody takes aim at Hard-to-Treat blood cancers
Disease control OngoingThis early-stage study tests a new antibody drug called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The main goals are to find the safest dose and check for side effects. The drug works by targeting a protein on cancer cells to stop …
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:40 UTC